Innovent Biologics Inc., a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (an IL-23p19 monoclonal antibody known as picankibart), as well as preclinical study results of IBI3013 (an IL-15 monoclonal antibody) and IAR129 (an IL-4R/OX40L bispecific antibody). These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.